Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Shz QIV, 2 doses · 1 trial · 2 indications
Number of participants reporting serious adverse reactions and Grade 3 adverse reactions following a vaccination with Shz QIV
| Arm | Type | Description |
|---|---|---|
| Group 1: 6 to 35 months | EXPERIMENTAL | Shz QIV 0.25 mL, 2 doses |
| Group 2: 3 to 8 years | EXPERIMENTAL | Shz QIV 0.5 mL, 2 doses |
| Group 3: 9 to 17 years | EXPERIMENTAL | Shz QIV 0.5 mL, single dose |
| Group 4: 18 to 60 years | EXPERIMENTAL | Shz QIV 0.5 mL, single dose |
| Group 5: 61 years and older | EXPERIMENTAL | Shz QIV 0.5 mL, single dose |
| Name | Type | Description |
|---|---|---|
| Shz QIV 0.25 mL, 2 doses | BIOLOGICAL | Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart. |
| Shz QIV 0.5 mL, 2 doses | BIOLOGICAL | Administered intramuscularly into the deltoid muscle, 28 days apart |
| Shz QIV 0.5 mL, single dose | BIOLOGICAL | Administered intramuscularly into the deltoid muscle. |
Inclusion Criteria: * Aged ≥ 6 months on the day of inclusion * For participants aged 6 months through 17 years: Informed consent form has been signed and dated by the parent(s) or another legally acceptable representative, if applicable. Additionally an assent form has been signed and dated by the...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
Shz QIV, 2 doses is an investigational quadrivalent influenza vaccine candidate developed by Sanofi. It is being studied for the prevention of influenza, also known as the flu, and was evaluated in a two-dose regimen in a Phase 1 clinical trial conducted in China.
Shz QIV, 2 doses is being developed for the prevention of influenza, or flu. The Phase 1 study enrolled healthy volunteers, including children as young as 6 months of age, and evaluated a two-dose schedule of the quadrivalent influenza vaccine candidate.
Shz QIV, 2 doses is developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. Sanofi is the sponsor of the clinical program evaluating this quadrivalent influenza vaccine candidate.
Shz QIV, 2 doses is in Phase 1 clinical development. It is an investigational vaccine candidate and has not been approved by the FDA. The completed Phase 1 trial assessed the safety of a single dose or two doses of the Shenzhen quadrivalent influenza vaccine.
Shz QIV, 2 doses was evaluated in one completed Phase 1 trial, NCT03430089, titled Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine. The trial enrolled 101 healthy volunteers in China, including participants aged 6 months and older, and used a controlled design.